Life Sciences
The company will use the funds to advance its brain shuttle platform that delivers RNAi therapies across the blood-brain barrier to help treat neurodegenerative diseases.
The pharma giant alleges that Hims & Hers is infringing its patents and misleading consumers by selling unsafe, unapproved compounded versions of its semaglutide drugs.
Patients can see the discounted prices on TrumpRx.gov, but the site does not currently sell the drugs.
Emerging Technologies
Sergio Calvo, general manager of theranostics at GE HealthCare, discusses the organization's use of theranostics in cancer care and how the technology combines targeted therapy with diagnostic imaging for personalized oncology care.
Despite tightening barriers to entry over the years, Europe and the US are still key to global expansion for Korean startups, says Sky Labs CEO Jack Byunghwan Lee.
AION Labs CEO, Mati Gill, discusses the company’s extensive backing from pharma and tech giants to build AI startups, and how AION is looking beyond AI to explore quantum technologies for research and development in drug discovery.
AION Labs CEO sat down with MobiHealthNews outside the JPM Healthcare Conference to discuss the acquisition he says represents a milestone for Israel’s biotech ecosystem.
Outside the JPM Healthcare Conference, Thomas Clozel, cofounder and CEO of Owkin, sat down with MobiHealthNews to discuss how the company is using AI to find causality in disease.
The San Francisco-based lab will house Eli Lilly experts in biology, science and medicine alongside NVIDIA AI model builders and engineers.
Private rheumatologist Dr Anandita Santosa in Singapore notes how current AI in healthcare priorities practically leave autoimmune and rheumatic diseases behind and shares what can be done to build a more comprehensive AI-driven preventive care ecosystem.